Wall Street analysts forecast that CRISPR Therapeutics (NASDAQ:CRSP) will announce earnings of ($0.67) per share for the current quarter, according to Zacks. Two analysts have made estimates for CRISPR Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.74). CRISPR Therapeutics posted earnings of ($0.54) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 24.1%. The firm is expected to announce its next earnings report on Thursday, May 10th.
On average, analysts expect that CRISPR Therapeutics will report full-year earnings of ($2.82) per share for the current fiscal year, with EPS estimates ranging from ($3.31) to ($2.53). For the next financial year, analysts expect that the company will report earnings of ($3.01) per share, with EPS estimates ranging from ($3.90) to ($2.27). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for CRISPR Therapeutics.
A number of brokerages have recently commented on CRSP. Zacks Investment Research raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. SunTrust Banks reissued a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Friday, March 9th. Piper Jaffray reissued an “overweight” rating and issued a $53.70 price target (down previously from $67.00) on shares of CRISPR Therapeutics in a report on Friday, March 9th. Barclays increased their price target on shares of CRISPR Therapeutics from $29.00 to $59.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, March 16th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $63.95.
Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of CRISPR Therapeutics by 17.2% in the 4th quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock valued at $505,000 after purchasing an additional 3,165 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of CRISPR Therapeutics by 22.8% in the 4th quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock valued at $737,000 after purchasing an additional 5,833 shares in the last quarter. Creative Planning purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $243,000. Paloma Partners Management Co purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $290,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $370,000. 26.61% of the stock is owned by institutional investors.
Shares of NASDAQ:CRSP traded up $0.60 during trading on Friday, reaching $43.27. The company had a trading volume of 2,771,686 shares, compared to its average volume of 1,142,825. The firm has a market capitalization of $2,012.61, a price-to-earnings ratio of -25.30 and a beta of 3.56. CRISPR Therapeutics has a 12 month low of $13.50 and a 12 month high of $61.24.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.67 Per Share” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3339301/brokerages-expect-crispr-therapeutics-crsp-will-announce-earnings-of-0-67-per-share.html.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.